Checking how accurately an Apple Watch measures heart and exercise data in heart disease
Compares Apple Watch readings with medical devices in adults with heart conditions.
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong, Hong KongSee the site
- Trial code
- Registry title
- Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Treatments tested
- Apple Watch Series 9
- Record updated
- 23 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 20 to 70 with a history of congenital heart disease, pulmonary hypertension, heart failure or coronary artery disease, and for athletes having a heart check. It tests smartwatch readings against medical devices.
- Age
- 20 to 70 years
- Sex
- All sexes can join.
- Disease stage
- A history of adult congenital heart disease, pulmonary hypertension, heart failure or coronary artery disease. Athletes having a cardiovascular assessment can also join.
Main reasons for not taking part
- Cannot do physical exertion, including the exercise test (CPX) and the 6-minute walk test (6MWT)
- Pregnancy
- Known allergy to parts of the study product
- Cannot give informed consent
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age 20 to 70 years old
- Ability to provide informed consent
- History of the following cardiovascular conditions:
- Adult congenital heart disease
- Pulmonary hypertension
- Heart failure
- Coronary artery disease
- Athletes undergoing cardiovascular assessment
Who cannot take part
- Known allergy to components of the investigational product
- Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)
- Pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 70 years old?
Where in Hong Kong
- Department of Medicine, Queen Mary HospitalHong Kong, Hong KongContact: Chun Ka WongNo longer taking part
About the trial
What the trial wants to find out
Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.
Read full original descriptionShow less
The Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.
This investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.
The group in the trial
- WatchXP
Participants will wear the investigational smartwatch (Apple Watch Series 9) concurrently for pre- and post-SaO2 and VO2max assessment during cardiopulmonary exercise test at the visit.
Treatment: Apple Watch Series 9
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)
- Plain-language title
- Checking how accurately an Apple Watch measures heart and exercise data in heart diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07663799, who can take part
- Record updated
- 23 June 2026